Rejing C2100 Fully Automated Chemiluminescence Immunoassay Analyzer--A New Generation of Fully Automated Whole Blood CLIA Platform

In high-throughput clinical laboratories, speed, automation, and versatility are crucial. The Hotgen C2100 fully automated chemiluminescence immunoassay analyzer stands out as a new generation automated CLIA solution. As the third-generation Whole Blood CLIA platform, the C2100 combines excellent throughput with advanced automation capabilities, meeting the high-intensity testing needs of large hospital laboratories, third-party testing centers, and large diagnostic institutions, also aligning with the product positioning of "Automatic CLIA: A New Era of Whole Blood CLIA Testing."

As Hotgen's new generation fully automated whole blood CLIA platform, the C2100 represents a new stage in whole blood chemiluminescence testing in terms of efficiency, automation, and clinical flexibility.

With a processing capacity of up to 200 tests/hour and direct whole blood testing capability, the C2100 significantly enhances automated immunoassay workflows, helping laboratories optimize processes while expanding specialty testing menus and service capabilities.

Excellent Design and Technical Specifications

The C2100 features a robust yet relatively compact design, measuring 690 mm × 760 mm × 690 mm and weighing approximately 100 kg, suitable for laboratories with performance and space utilization requirements. The system is equipped with a 17.3-inch touchscreen for intuitive operation and real-time monitoring.

Main technical parameters include:

• Testing speed: up to 200 tests/hour

• First result time: as fast as 12 minutes

• Sample positions: 50 (5 × 10 layout)

• Reagent positions: 15, supporting 24-hour continuous refrigeration (2°C–8°C)

• Reaction cup capacity: up to 400

• Sample needle: stainless steel with liquid level detection, minimum sample volume 10 μL

• Carryover rate: very low (AFP carryover ≤ 10⁻⁵)

These configurations enable the C2100 to efficiently achieve continuous random testing. The system supports various sample types such as serum, plasma, whole blood, and urine, providing greater flexibility for diverse clinical workflows.

Its automated architecture and compatibility with whole blood testing help improve work efficiency while reducing pre-sample processing steps.

Groundbreaking Whole Blood Testing Capability

One of the most notable features of the C2100 is its whole blood testing capability. Cardiac markers and inflammation indicators can be directly tested using EDTA anticoagulated whole blood samples, often without the need for centrifugation. This capability allows laboratories to achieve faster turnaround times in fully automated environments and improve response efficiency in time-sensitive scenarios such as emergencies.

The analyzer integrates automatic capping, automatic mixing, and a built-in hematocrit (HCT) calibration module. Even when dealing with whole blood samples, these features help ensure result accuracy and consistency, reducing pre-analytical errors and shortening TAT. Laboratories can more efficiently complete tests in the same blood collection tube, optimizing sample utilization and enhancing overall efficiency in high-pressure environments.

As a third-generation whole blood CLIA platform, the C2100 helps enhance laboratory support capabilities in emergency diagnostics and intensive care scenarios.

Innovative Testing Technology for Superior Performance

The C2100 adopts a small molecule sandwich detection technology, particularly suitable for thyroid function testing. Compared with traditional methods, this technology helps achieve higher sensitivity, stronger specificity, wider detection range, and better reagent stability, providing more reliable data support for clinical diagnostics and efficacy monitoring.

Orbital sample loading further enhances system usability, achieving true random testing capability. Operators can load new samples at any time without interrupting ongoing testing processes, which is especially important for laboratories that need to handle unpredictable workloads and urgent STAT samples.

The combination of innovative testing technology and high-throughput automation makes the C2100 one of the important solutions for modern central laboratories.

Specialized Clinical Applications

The C2100 is well-suited for multiple key diagnostic areas.

In tuberculosis management, the system supports the TB-IGRA testing process, which can process and detect IFN-γ based on whole blood samples for tuberculosis infection screening and auxiliary diagnosis. The automated process can reduce manual operation and enhance consistency, suitable for screening and clinical testing needs in areas with high tuberculosis prevalence.

In gastric health management, the C2100 supports indicators related to gastric function and risk stratification, such as Gastrin-17, Pepsinogen I/II, and Helicobacter pylori antibodies, for applications like disease risk assessment, follow-up management, and population screening.

Additionally, the analyzer's cytokine detection capability can support intensive care by helping evaluate inflammatory responses and immune status for clinical management scenarios such as sepsis monitoring. Its automation and rapid result capability help improve decision-making efficiency in ICU settings.

These specialized testing capabilities, along with routine tests such as cardiac markers, tumor markers, and hormones, allow the C2100 to serve multiple departments and support various testing needs with a single device.

The whole blood testing advantages of the C2100 further enhance its value in time-sensitive clinical applications, where process simplification and rapid reporting are particularly critical.

Workflow Efficiency and Laboratory Integration

The C2100 is designed to integrate into modern laboratory information and automation systems. The system supports LIS/HIS connectivity, enabling automatic data transmission and reducing administrative workload. The large touchscreen can intuitively display operation guidelines, running status, and quality control information.

Laboratories can gain the following advantages:

• Automated quality control and calibration processes

• Low carryover rate and good repeatability

• Reagents support 24-hour standby refrigeration

• Higher "off-machine operation" level, reducing manual intervention time

• Support for orbital automated production lines, achieving higher levels of laboratory automation

These features help laboratories enhance testing capabilities while maintaining quality standards and reducing unit operating costs.

Its compatibility with laboratory automation track systems and continuous random testing capability make the C2100 suitable for large clinical testing centers.

Advantages for High-Throughput Laboratories

Compared to other small benchtop systems, the C2100 is optimized for high-sample-volume institutions. Its higher testing speed and larger sample and reaction cup capacity make it suitable for central laboratories, large hospitals, and commercial diagnostic service institutions.

The combination of whole blood testing, rapid results, and a rich testing menu enables laboratories to integrate testing platforms, reduce equipment numbers, and simplify staff training. The system's stable operation and low-maintenance design also help improve uptime, ensuring continuous service capability.

By combining whole blood testing with high-throughput automation, the C2100 can help laboratories achieve faster TAT and higher overall operational efficiency.

Conclusion: How the C2100 Enhances Laboratory Productivity

Hotgen has positioned the C2100 as one of the flagship models in its automated CLIA product line. By combining rapid whole blood testing, advanced detection methods, high-capacity processing capability, and good compatibility with laboratory automation, the C2100 can meet the performance standards required in demanding laboratory environments.

As Hotgen's flagship third-generation whole blood CLIA platform, the C2100 demonstrates the company's continuous innovation capability in the field of fully automated chemiluminescence immunoassays.

From tuberculosis and gastric function-related testing to cytokine monitoring and routine high-throughput immunoassays, the C2100 provides a reliable, scalable, and future-oriented analysis platform for laboratories, helping institutions enhance testing efficiency and clinical support capabilities with minimal manual intervention.